<DOC>
	<DOCNO>NCT01410370</DOCNO>
	<brief_summary>The aim study evaluate clinical efficacy safety continuous Endostar infusion combine radiotherapy treatment brain metastasis .</brief_summary>
	<brief_title>Continuous Endostar Infusion Combined With Radiotherapy Patients With Brain Metastases</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<criteria>Histologically confirm malignancy presence intraparenchymal brain metastasis Karnofsky performance status ≥ 40 Measurable disease accord RECIST criterion Hematologic function : WBC ≥ 4.0×109/L , PLT ≥ 80×109/L , Hb ≥ 90g/L Renal function : Cr ≤ 2.0×ULN Hepatic function : BIL ≤ 2.0×ULN , ALT/AST ≤ 5.0×ULN Adequate cardiac function Life expectancy ≥ 3 month Evidence bleed diathesis serious infection Serious cardiovascular disease ( congestive heart failure , uncontrollable arrhythmia , unstable angina , myocardial infarction , serious heart valve disease , resistant hypertension ) Uncontrollable mental nervous disorder Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Endostar</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>Brain Metastases</keyword>
</DOC>